https://doi.org/10.4081/reumatismo.2005.4s.22

Biologic therapy with anti-TNFa in spondyloarthritides and other autoimmune diseases

Vol. 57 No. s4 (2005)
Abstract Views: 757
PDF: 1058
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

G. Lapadula
office@pagepress.org
Objective: To evaluate the efficacy of the anti-TNFa (Tumor Necrosis Factor alpha) drugs in a variety of pathologic conditions such as psoriatic arthritis, undifferentiated entheso-arthritides, chronic inflammatory bowel diseases, adult onset Still’s disease, Behcet disease. Methods: Review of all published studies evaluating the efficacy of these drugs (mainly infliximab and etanercept, adalimumab to a lesser degree) on the above diseases. Results: Results are reported for each pathologic condition. Both drugs showed to be very efficacious in all the above conditions, except Crohn disease where etanercept does not seem adequate. Conclusions: Both drugs work extremely well, even though comparison between infliximab and etanercept efficacy cannot be performed, due to the lack of a direct comparison.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Lapadula, G. (2005). Biologic therapy with anti-TNFa in spondyloarthritides and other autoimmune diseases. Reumatismo, 57(s4), 22–29. https://doi.org/10.4081/reumatismo.2005.4s.22

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.